eptinezumab
Cold Chain RequiredFDA Approved, Limited Global Availability
Description
Eptinezumab is a humanized monoclonal antibody that targets calcitonin gene-related peptide (CGRP). It is the first intravenous CGRP antagonist approved for migraine prevention, offering quarterly dosing with rapid onset of preventive effects.
Indications & Therapeutic Use
migraine prevention, chronic migraine, episodic migraine
Global Availability (3 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
eptinezumab
| Generic Name | eptinezumab |
| Brands | 1 brand available |
| Active Ingredient | eptinezumab-jjmr |
| Drug Class | migraine prevention |
| Manufacturer | Lundbeck |
| Dosage Forms | Intravenous solution, 100mg/mL |
| Medical Code | N02CD05 |
| Orphan Status | No |
| Cold Chain | Required |
| Lead Time | 30 days |
| Reg. Status | FDA Approved, Limited Global Availability |
| Clinical Trial | NCT02559895 |
| Countries | 3 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations4 Validated Nodes